Bifogade filer
Change in Number of Shares and Votes in Ascelia Pharma AB
Kurs
+2,04%
Likviditet
1,36 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2027-02-11 | 07:30 | Bokslutskommuniké 2026 |
| 2026-11-05 | 07:30 | Kvartalsrapport 2026-Q3 |
| 2026-08-20 | 07:30 | Kvartalsrapport 2026-Q2 |
| 2026-05-12 | - | Kvartalsrapport 2026-Q1 |
| 2026-05-05 | - | X-dag ordinarie utdelning ACE 0.00 SEK |
| 2026-05-04 | - | Årsstämma |
| 2026-02-05 | - | Bokslutskommuniké 2025 |
| 2025-11-05 | - | Kvartalsrapport 2025-Q3 |
| 2025-08-21 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-16 | - | Kvartalsrapport 2025-Q1 |
| 2025-05-08 | - | X-dag ordinarie utdelning ACE 0.00 SEK |
| 2025-05-07 | - | Årsstämma |
| 2025-02-25 | - | Extra Bolagsstämma 2025 |
| 2025-02-07 | - | Bokslutskommuniké 2024 |
| 2024-11-07 | - | Kvartalsrapport 2024-Q3 |
| 2024-10-30 | - | Extra Bolagsstämma 2024 |
| 2024-08-15 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-16 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-07 | - | X-dag ordinarie utdelning ACE 0.00 SEK |
| 2024-05-06 | - | Årsstämma |
| 2024-02-09 | - | Bokslutskommuniké 2023 |
| 2023-11-13 | - | Extra Bolagsstämma 2023 |
| 2023-11-08 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-18 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-11 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-05 | - | X-dag ordinarie utdelning ACE 0.00 SEK |
| 2023-05-04 | - | Årsstämma |
| 2023-02-10 | - | Bokslutskommuniké 2022 |
| 2022-11-04 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-18 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-11 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-06 | - | X-dag ordinarie utdelning ACE 0.00 SEK |
| 2022-05-05 | - | Årsstämma |
| 2022-02-10 | - | Bokslutskommuniké 2021 |
| 2021-11-04 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-12 | - | Kvartalsrapport 2021-Q1 |
| 2021-05-06 | - | X-dag ordinarie utdelning ACE 0.00 SEK |
| 2021-05-05 | - | Årsstämma |
| 2021-04-13 | - | Extra Bolagsstämma 2021 |
| 2021-02-16 | - | Bokslutskommuniké 2020 |
| 2020-11-05 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-07 | - | X-dag ordinarie utdelning ACE 0.00 SEK |
| 2020-05-06 | - | Årsstämma |
| 2020-05-03 | - | Kvartalsrapport 2020-Q1 |
| 2019-11-15 | - | X-dag ordinarie utdelning ACE 0.00 SEK |
| 2019-08-22 | - | Bokslutskommuniké 2019 |
| 2019-05-15 | - | Kvartalsrapport 2019-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
During April, the registered number of shares and votes in Ascelia Pharma AB (”Ascelia Pharma”) has increased due to the directed new issue of ordinary shares which was announced by Ascelia Pharma on 23 April 2026. As of 30 April 2026, the total number of shares in Ascelia Pharma amounts to 134,569,246 shares, whereof 133,535,460 are ordinary shares with one vote each and 1,033,786 are series C shares with 1/10 vote each. The total number of votes in Ascelia Pharma as of 30 April 2026 amounts to 133,638,838.6.
About us
Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance and Oncoral – in development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com.
Contacts
Magnus Corfitzen, CEO
Email: moc@ascelia.com
Tel: +46 735 179 118
Anton Hansson, CFO
Email: anton.hansson@ascelia.com
Tel: +46 735 179 113
This information was submitted for publication, through the agency of the contact persons set out above.
This information is information that Ascelia Pharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2026-04-30 11:00 CEST.